In September, Agilent completed its acquisition of Biovectra, a contract development and manufacturing organization. Now, President Trump has threatened Canada with tariffs.
The deal with the Chinese manufacturer is meant to accelerate the development and commercialization of Oramed’s oral insulin and other oral drug delivery technologies.
